Endoscopic Ultrasound-Guided Brachytherapy of Yttrium-90 Implantation Into Pancreas: A Dose-Escalation Pilot Study

Abstract

Intratumoral brachytherapy enables higher dose treatment and reduces damage to adjacent tissues. We first validated the feasibility and safety of endoscopic ultrasound (EUS)-guided Yttrium-90 (⁹⁰Y) microspheres implantation in a porcine model. Under EUS guidance, ⁹⁰Y-loaded microspheres were implanted into the pancreas of 10 miniature pigs. The first pig was implanted with 10 MBq particles. Subsequently, nine pigs were sequentially included in the low- (20 MBq), medium- (40 MBq), and high-dose (60 MBq) groups. Positron emission tomography (PET)/CT imaging was used to check the occurrence of particle displacement postoperatively. After euthanasia, the pancreas and adjacent organs were excised for histological examination and residue radiation detection. The absorbed doses demonstrated safe in the porcine model were further in the xenograft model and KRAS^LSL/+Trp53^FL/FLPtfqa^Cre/+ mouse model. EUS-guided implantations of ⁹⁰Y-loaded microspheres were successful in all animals. Two pigs had mild serum amylase elevation in the high-dose group and the abnormal index returned to baseline without interventions. The volume of necrotic lesions ranged from 255.76 to 745.57 mm³. In KPC mouse model, PET/CT imaging demonstrated a significant decrease in maximum standardized uptake value (SUVmax) after ⁹⁰Y implantation. EUS-guided ⁹⁰Y-loaded carbon microsphere implantation could serve as a safe and feasible technique at ultrahigh dose for pancreatic cancer brachytherapy.

Keywords

brachytherapy / endoscopic ultrasound / pancreatic cancer / porcine model / Yttrium-90

References

[1] T. F. Stoop, R. T. Theijse, L. W. F. Seelen, et al., “Preoperative Chemotherapy, Radiotherapy and Surgical Decision-Making in Patients With Borderline Resectable and Locally Advanced Pancreatic Cancer,” Nature Reviews Gastroenterology & Hepatology 21, no. 2 (2024): 101–124.

[2] E. Versteijne, M. Suker, K. Groothuis, et al., “Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial,” Journal of Clinical Oncology 38, no. 16 (2020): 1763–1773.

[3] C. N. Hurt, S. Falk, T. Crosby, et al., “Long-Term Results and Recurrence Patterns From SCALOP: A Phase II Randomised Trial of Gemcitabine-or Capecitabine-Based Chemoradiation for Locally Advanced Pancreatic Cancer,” British Journal of Cancer 116, no. 10 (2017): 1264–1270.

[4] S. Krishnan, A. S. Chadha, Y. Suh, et al., “Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation,” International Journal of Radiation and Oncology in Biology and Physics 94, no. 4 (2016): 755–765.

[5] A. Torgeson, S. Lloyd, D. Boothe, et al., “Multiagent Induction Chemotherapy Followed by Chemoradiation Is Associated With Improved Survival in Locally Advanced Pancreatic Cancer,” Cancer 123, no. 19 (2017): 3816–3824.

[6] E. Versteijne, J. L. van Dam, M. Suker, et al., “Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial,” Journal of Clinical Oncology 40, no. 11 (2022): 1220–1230.

[7] C. M. Taniguchi, J. M. Frakes, T. A. Aguilera, et al., “Stereotactic Body Radiotherapy With or Without Selective Dismutase Mimetic in Pancreatic Adenocarcinoma: An Adaptive, Randomised, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial,” The Lancet Oncology 24, no. 12 (2023): 1387–1398.

[8] M. de Scordilli, A. Michelotti, D. Zara, et al., “Preoperative Treatments in Borderline Resectable and Locally Advanced Pancreatic Cancer: Current Evidence and New Perspectives,” Critical Reviews in Oncology/Hematology 186 (2023): 104013.

[9] M. H. G Katz, Q. Shi, J. Meyers, et al., “Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial,” JAMA Oncology 8, no. 9 (2022): 1263–1270.

[10] Q. P. Janssen, J. L. van Dam, L. R. Prakash, et al., “Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study,” Journal of the National Comprehensive Cancer Network: JNCCN 20, no. 7 (2022): 783–791.e781.

[11] J. Naidu, D. Bartholomeusz, J. Zobel, et al., “Combined Chemotherapy and Endoscopic Ultrasound-Guided Intratumoral 32P Implantation for Locally Advanced Pancreatic Adenocarcinoma: A Pilot Study,” Endoscopy 54, no. 1 (2022): 75–80.

[12] R. L. J. van Wanrooij, M. Bronswijk, R. Kunda, et al., “Therapeutic Endoscopic Ultrasound: European Society of Gastrointestinal Endoscopy (ESGE) Technical Review,” Endoscopy 54, no. 3 (2022): 310–332.

[13] M. Ashat, R. El-Abiad, A. Shrigiriwar, and M. A. Khashab, “Interventional Endoscopic Ultrasound: Current Status and Future Frontiers,” American Journal of Gastroenterology 118, no. 10 (2023): 1768–1778.

[14] K. X. Wang, Z. D. Jin, Y. Q. Du, et al., “EUS-Guided Celiac Ganglion Irradiation With Iodine-125 Seeds for Pain Control in Pancreatic Carcinoma: A Prospective Pilot Study,” Gastrointestinal Endoscopy 76, no. 5 (2012): 945–952.

[15] M. J. Levy, M. D. Topazian, M. J. Wiersema, et al., “Initial Evaluation of the Efficacy and Safety of Endoscopic Ultrasound-Guided Direct Ganglia Neurolysis and Block,” American Journal of Gastroenterology 103, no. 1 (2008): 98–103.

[16] P. J. Ross, H. S. Wasan, D. Croagh, et al., “Results of a Single-Arm Pilot Study of (32)P Microparticles in Unresectable Locally Advanced Pancreatic Adenocarcinoma With Gemcitabine/Nab-Paclitaxel or FOLFIRINOX Chemotherapy,” ESMO Open 7, no. 1 (2022): 100356.

[17] Y. H. Gholami, N. Wilson, D. James, and Z. Kuncic, “Toward Personalized Dosimetry With (32)P Microparticle Therapy for Advanced Pancreatic Cancer,” International Journal of Radiation and Oncology in Biology and Physics 99, no. 4 (2017): 1029–1038.

[18] G. N. Cohen, J. J. Munro 3rd, A. Kirov, et al., “32P Brachytherapy Conformal Source Model RIC-100 for High-Dose-Rate Treatment of Superficial Disease: Monte Carlo Calculations, Diode Measurements, and Clinical Implementation,” International Journal of Radiation and Oncology in Biology and Physics 88, no. 3 (2014): 746–752.

[19] R. Salem, A. C. Gordon, S. Mouli, et al., “Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma,” Gastroenterology 151, no. 6 (2016): 1155–1163.e1152.

[20] V. Vilgrain, H. Pereira, E. Assenat, et al., “Efficacy and Safety of Selective Internal Radiotherapy With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma (SARAH): An Open-Label Randomised Controlled Phase 3 Trial,” Lancet Oncology 18, no. 12 (2017): 1624–1636.

[21] J. L. Schaal, J. Bhattacharyya, J. Brownstein, et al., “Brachytherapy via a Depot of Biopolymer-Bound (131)I Synergizes With Nanoparticle Paclitaxel in Therapy-Resistant Pancreatic Tumours,” Nature Biomedical Engineering 6, no. 10 (2022): 1148–1166.

[22] J. Bai, Q. Yu, Y. Wang, et al., “Iodine-125 Brachytherapy Suppresses Tumor Growth and Alters Bone Metabolism in a H1299 Xenograft Mouse Model,” Medical Oncology (Northwood, London, England) 40, no. 2 (2023): 72.

[23] M. Palta, D. Godfrey, K. A. Goodman, et al., “Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline,” Practical Radiation Oncology 9, no. 5 (2019): 322–332.

[24] W. A. Hall, L. A. Dawson, T. S. Hong, et al., “Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma,” Journal of Clinical Oncology 39, no. 34 (2021): 3773–3777.

[25] P. Ghaneh, D. Palmer, S. Cicconi, et al., “Immediate Surgery Compared With Short-Course Neoadjuvant Gemcitabine Plus Capecitabine, FOLFIRINOX, or Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Cancer (ESPAC5): A Four-Arm, Multicentre, Randomised, Phase 2 Trial,” Lancet Gastroenterology & Hepatology 8, no. 2 (2023): 157–168.

[26] J. Ye, N. W. Gavras, D. C. Keeley, et al., “CD73 and PD-L1 Dual Blockade Amplifies Antitumor Efficacy of SBRT in Murine PDAC Models,” Journal for Immunotherapy of Cancer 11, no. 5 (2023): e006842.

[27] C. W. F. van Eijck, D. A. M. Mustafa, D. Vadgama, et al., “Enhanced Antitumour Immunity Following Neoadjuvant Chemoradiotherapy Mediates a Favourable Prognosis in Women With Resected Pancreatic Cancer,” Gut 73, no. 2 (2024): 311–324.

[28] V. Chew, Y. H. Lee, L. Pan, et al., “Immune Activation Underlies a Sustained Clinical Response to Yttrium-90 Radioembolisation in Hepatocellular Carcinoma,” Gut 68, no. 2 (2019): 335–346.

[29] S. P. Kim, C. Cohalan, N. Kopek, and S. A. Enger, “A Guide to (90)Y Radioembolization and Its Dosimetry,” Physical Medicine 68 (2019): 132–145.

[30] W. Chen, W. Peng, R. Wang, et al., “Exosome-Derived tRNA Fragments tRF-GluCTC-0005 Promotes Pancreatic Cancer Liver Metastasis by Activating Hepatic Stellate Cells,” Cell Death & Disease 15, no. 1 (2024): 102.

[31] T. N. Fujimoto, L. E. Colbert, Y. Huang, et al., “Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer,” Cancer Research 79, no. 9 (2019): 2327–2338.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.